In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 326 to 350 of 375

Sort by

Type: Guidance`Remove $Type: Guidance filter`

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Tafasitamab with lenalidomide and R-CHOP for untreated high-intermediate-risk or high-risk diffuse large B-cell lymphoma [ID6568]	Technology appraisal guidance	10 June 2027
Tafasitamab with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6413]	Technology appraisal guidance	15 July 2026
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]	Technology appraisal guidance	TBC
Tarlatamab for treating extensive stage small-cell lung cancer that has progressed after platinum-based chemotherapy [ID6617]	Technology appraisal guidance	13 January 2027
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women [ID1401]	Technology appraisal guidance	TBC
Technologies for the rapid diagnosis of endometriosis	Health technology evaluation	8 October 2026
Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]	Technology appraisal guidance	TBC
Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259]	Technology appraisal guidance	8 April 2026
Teprotumumab for treating thyroid eye disease (deferred appraisal of D1) [ID6756]	Technology appraisal guidance	TBC
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps [ID6379]	Technology appraisal guidance	9 September 2026
Third molars (impacted) - prophylactic removal [ID898]	Technology appraisal guidance	TBC
Tiragolumab with atezolizumab and bevacizumab for untreated unresectable or advanced hepatocellular carcinoma [TSID12238]	Technology appraisal guidance	TBC
Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]	Technology appraisal guidance	TBC
Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation [ID6250]	Technology appraisal guidance	TBC
Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122]	Technology appraisal guidance	TBC
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]	Technology appraisal guidance	10 February 2027
Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer ID6304	Technology appraisal guidance	TBC
Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]	Technology appraisal guidance	TBC
Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment [ID3753]	Technology appraisal guidance	12 June 2026
Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]	Highly specialised technology	17 March 2027
Tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis [ID6351]	Technology appraisal guidance	TBC
Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]	Technology appraisal guidance	TBC
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]	Technology appraisal guidance	2 December 2026
Total hip arthroplasty using the superpath approach for osteoarthritis	Interventional procedures guidance	TBC
Tovorafenib for treating relapsed or refractory paediatric low-grade glioma with BRAF fusion or rearrangement or BRAF V600 mutation in people 6 months and over [ID6557]	Technology appraisal guidance	TBC

Results per page

10
25
50
All